期刊文献+

气相色谱法测定盐酸普拉格雷中的异丙叉丙酮和佛尔酮

Determination of Mesityl Oxide and Phorone in Prasugrel Hydrochloride by Gas Chromatography
原文传递
导出
摘要 建立了气相色谱法测定盐酸普拉格雷(1)中含警示结构不饱和酮的异丙叉丙酮(2)和佛尔酮(3)。色谱柱采用DB-624毛细管柱(30 m×0.53 mm×3.0μm),程序升温,采用直接进样法进行测定。结果显示,2、3在5~30μg/ml内线性关系良好,平均回收率(n=9)分别为101.25%、102.23%,RSD分别为0.66%、0.79%。2、3的定量限分别为2.77、2.89μg/ml,检测限分别为1.11、1.16μg/ml。建立的方法专属性强、灵敏度高、耐用性好,可用于1中2和3的测定。 A gas chromatographic method was established for determination of the structural alerts,the unsaturated ketones mesityl oxide(2)and phorone(3),in prasugrel hydrochloride(1).The DB-624 capillary column(30 m×0.53 mm×3.0μm)was used with temperature programming,and the direct injection method was used for the determination.The results showed that it was linear for 2 and 3 in the range of 5-30μg/ml,the average recoveries(n=9)of 2 and 3 were 101.25%and 102.23%,with the RSDs of 0.66%and 0.79%,respectively.The limits of quantification of 2 and 3 were respectively 2.77 and 2.89μg/ml,and the limits of detection were respectively 1.11 and 1.16μg/ml.The established method has strong specificity,high sensitivity and good durability,which can be used for the determination of 2 and 3 in 1.
作者 孙建合 卢红华 侯继鹏 郝贵周 张贵民 SUN Jianhe;LU Honghua;HOU Jipeng;HAO Guizhou;ZHANG Guimin(National Engineering Research Center of Chiral Drugs,Lunan Pharmaceutical Group,Linyi 273400)
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2022年第6期901-903,共3页 Chinese Journal of Pharmaceuticals
关键词 气相色谱 盐酸普拉格雷 异丙叉丙酮 佛尔酮 gas chromatography prasugrel hydrochloride mesityl oxide phorone
  • 相关文献

参考文献3

二级参考文献30

  • 1[1]Brandt JT,Farid NA,Jakubowski JA,et al.Treating cardiovascular diseases with a compound of formula(I)(CS 747-Prasugrel;RN 150322-43-4)[P].World(PTC)Patent:WO098713,2004-11-18.
  • 2[2]Wiviott SD,Antman EM,Gibson CM,et al.Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes:design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrd Thrombolysis In Myocardial Infarction 38(TRITON-TIMI 38)[J].Am Heart J,2006,152(4):627-635.
  • 3[5]Wiviott SD,Braunwald E,Mecabe CH,et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2007,357(20):2001 -2015.
  • 4[6]Serahruany VL,Midei MG,Meilman H,et al.Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting:the subset from the JUMBO study[J].Postgrad Med J,2006,82(968):404-410.
  • 5[7]Sugidachl A,Asai F,Ogawa T,et al.The in vivo pharmacologiccal profile of CS-747,a novel antiplatelet agent with platelet ADP receptor antagonist properties[J].Br J Pharmacol,2000,129(7):1439-1446.
  • 6[8]Brandt JT,Payne CD,Wiviott SD,et al.A comparison of prasugrel and clopidogrel loading doses on platelet function:magnitude of platelet inhibition is related to active metabolite formation[J].Am Heart J,2007,153(i):66.e9 -e16.
  • 7[9]Wallentin L,Varenhorst C,James S,et al.Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease[J].Eur Heart J,2007,29(1):21 -30.
  • 8[10]Wiviott SD,Antman EM,Winters KJ,et al.Randomized comparison of prasugrel (CS-747,LY640315),a novel thienopyridine P2Y12 antagonist,with clopidogrel in pereutaneous coronary intervention[J].Circulation,2005,111 (25):3366-3373.
  • 9[11]Rehmel JL,Eckstein JA,Farid NA,et al.Interactions of two major metabolites of prasugrel,a thienopyridine antiplatelet agent,with the cytochromes P450[J].Drug Metab Dispos,2006,34(4):600 -607.
  • 10[12]Brandt JT,Farid NA,Jakubowski JA,et al.Dosage regimen for prasugrel[P].World(PTC) Patent:WO-138317,2006-12-28.

共引文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部